Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pfizer Anticipates A 'Bolus Of Revenue' From RSV, Prevnar 20 Launches This Year

May 02 2023

• By Jessica Merrill

vaccine — Pfizer expects new vaccines to deliver a boost to revenues • Source: Shutterstock

Related Content

Keeping Track: Showers Of Approvals In US FDA’s May Forecast

Apr 29 2023

Pfizer’s RSV Vaccine Springs Another Surprise, This Time In Maternal Use

Nov 01 2021

For New RSV Shots, ‘Vaccine Fatigue’ Could Be One Of The Biggest Barriers

Apr 11 2023

Pfizer Pays $43bn For Seagen With Goal Of Rapidly, Globally Advancing ADCs

Mar 13 2023

Related Companies

Pfizer Inc.

GSK plc

BioNTech SE

Additional Topics

Sales & Earnings Vaccines Launches Business Strategies Commercial Companies BioPharmaceutical

More from Earnings

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window